Compare XFOR & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XFOR | KIO |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 143 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 461.1M |
| IPO Year | N/A | 2011 |
| Metric | XFOR | KIO |
|---|---|---|
| Price | $4.22 | $11.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 386.6K | 138.4K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $10.65 |
| 52 Week High | $4.83 | $12.83 |
| Indicator | XFOR | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 48.04 |
| Support Level | $3.58 | $10.66 |
| Resistance Level | $4.54 | $11.25 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 83.58 | 33.33 |
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.